Ensysce Biosciences (ENSCW) Other Non-Current Assets (2020 - 2025)
Ensysce Biosciences (ENSCW) reported Other Non-Current Assets of $83332.0 for Q4 2025, down 67.0% year-over-year from $252550.0 in Q4 2024, and down 34.67% quarter-over-quarter from $127551.0 in Q3 2025.
Ensysce Biosciences (ENSCW) Other Non-Current Assets (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of Other Non-Current Assets data on file, last reported at $83332.0 in Q4 2025.
- Other Non-Current Assets for Q4 2025 came in at $83332.0, down 67.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $83332.0 (down 67.0% YoY), and the FY2025 annual result was $83332.0, down 67.0% from the prior year.
- Other Non-Current Assets retreated to $83332.0 in Q4 2025 per ENSCW's latest filing, from $127551.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $838091.0 in Q2 2021 and troughed at $83332.0 in Q4 2025.
- A 5-year average of $467837.3 and a median of $460883.0 in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2021 and 2025: Other Non-Current Assets surged 19867.09% in 2021, then plunged 67.0% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $754756.0 in 2021, then decreased by 22.37% to $585883.0 in 2022, then declined by 28.45% to $419217.0 in 2023, then plunged by 39.76% to $252550.0 in 2024, then sank by 67.0% to $83332.0 in 2025.
- Business Quant data shows ENSCW's Other Non-Current Assets at $83332.0 in Q4 2025, $127551.0 in Q3 2025, and $292860.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ensysce Biosciences | - | - | - | 83,332.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 83,332.00 |
| Sep 30, 2025 | 127,551.00 |
| Jun 30, 2025 | 292,860.00 |
| Mar 31, 2025 | 210,883.00 |
| Dec 31, 2024 | 252,550.00 |
| Sep 30, 2024 | 294,217.00 |
| Jun 30, 2024 | 335,883.00 |
| Mar 31, 2024 | 377,550.00 |
| Dec 31, 2023 | 419,217.00 |
| Sep 30, 2023 | 460,883.00 |
| Jun 30, 2023 | 502,550.00 |
| Mar 31, 2023 | 544,217.00 |
| Dec 31, 2022 | 585,883.00 |
| Sep 30, 2022 | 627,550.00 |
| Jun 30, 2022 | 671,423.00 |
| Mar 31, 2022 | 713,090.00 |
| Dec 31, 2021 | 754,756.00 |
| Sep 30, 2021 | 796,423.00 |
| Jun 30, 2021 | 838,091.00 |
| Dec 31, 2020 | 3,780.00 |